Antibiotic development and resistance

International Encyclopedia of Public Health

Volumn , Issue , 2008, Pages 200-211

  Straand, J ^a   Gradmann, C ^a   Lindbaek M ^a   Simonsen, G S ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Antibiotics; Bacterial infections; Chemotherapeutics; History of medicine; Public health; Resistance

Indexed keywords

EID: 78650728635     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012373960-5.00367-1     Document Type: Chapter

References (31)

1. Arason V.A., Sigurdsson J.A., Erlendsdottir H., Gudmundsson S., Kristinsson K.G. The role of antimicrobial use in the epidemiology of resistant pneumococci: A 10-year follow up. Microbiological Drug Resistance 2006, 12:169-176.
2. Barber M., Rozwadowska-Dowzenko M. Infection by penicillin-resistant staphylococci. The Lancet 1948, ii:641-644.
3. Cassell G.H., Mekalanos J. Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance. Journal of the American Medical Association 2001, 285:601-605.
4. Cosgrove S.E., Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clinical Infectious Disease 2003, 36:1433-1437.
5. Cosgrove S.E., Sakoulas G., Perencevich E.N., Schwaber M.J., Karchmer A.W., Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clinical Infectious Disease 2003, 36:53-59.
6. Goossens H., Ferech M., VanderStichele R., Elseviers M. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. The Lancet 2005, 365:579-587. ESAC Project Group.
7. The Swann Report 1969, Joint Committee on the Use of Antibiotics in Animal Husbandry and Veterinary Medicine, Her Majesty's Stationary Office, London.
8. Kyaw M.H., Lynfield R., Schaffner W., et al. Active bacterial core surveillance of the emerging infections program network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. The New England Journal of Medicine 2006, 354:1455-1463. and (erratum) 355: 638.
9. Lautenbach E., Strom B.L., Bilker W.B., Patel J.B., Edelstein P.H., Fishman N.O. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clinical Infectious Disease 2001, 33:1288-1294.
10. Mosse J.R. Of the use of yeast in the treatment of boils. The Lancet 1852, ii:113.
11. American Journal of Infection Control 2004, 32:470-485. National Nosocomial, Infections Surveillance (NNIS) System, Report.
12. Seppala H., Klaukka T., Vuopio-Varkila J., Muotiala A., Helenius H., Lager K., Huovinen P. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. The New England Journal of Medicine 1997, 337:441-446.
13. Wenzel R.P., Edmond M.B. Managing antibiotic resistance. The New England Journal of Medicine 2000, 343:1961-1963.
14. WHO Global Strategy for Containment of Antimicrobial Resistance 2001, World Health Organization, WHO, Geneva, Switzerland.
15. Ayliffe G.A.J., English M.P. Hospital Infection from Miasmas to MRSA 2003, Cambridge University Press, Cambridge, UK.
16. Brandt A.M. No Magic Bullet. A Social History of Venereal Disease in the United States since 1880 1987, Oxford University Press, New York.
17. Bud R. Penicillin, Triumph and Tragedy 2007, Oxford University Press, Oxford, UK.
18. Duckett S. Ernest Duchesne and the concept of fungal antibiotic therapy. The Lancet 1999, 354:2068-2071.
19. Lesch J.E. The First Miracle Drugs: How the Sulfa Drugs Transformed Medicine 2007, Oxford University Press, New York.
20. Levy S.B. The Antibiotic Paradox 1992, Plenum Press, New York.
21. Levy S.B. The challenge of antibiotic resistance. Scientific American 1998, 298:46-53.
22. Müller-Jahnke W.D., Friederich C. Geschichte der Arzneimitteltherapie 1996, Deutscher Apotheker Verlag, Stuttgart.
23. Sauerteig L. Krankheit, Sexualität und Gesellschaft: Geschlechtskrankheiten und Gesundheitspolitik in Deutschland im 19. und frühen 20. Jahrhundert 1999, Steiner, Stuttgart.
24. Wainwright M. Miracle Cure. The Story of Penicillin and the Golden Age of Antibiotics 1990, Basil Blackwell, Cambridge, MA.
25. Wimmer W. Wir haben fast immer was Neues: Gesundheitswesen und Innovation der Pharma-Industrie in Deutschland 1880-1935 1994, Duncker & Humblodt, Berlin.
26. - Action on Antibiotic Resistance (REACT). http://www.react-group.org.
27. - Alliance for the Prudent Use of Antibiotics (APUA). http://www.tufts.edu/med/apua/home.html.
28. - Centers for Disease Control and Prevention (CDC). http://www.cdc.gov/drugresistance/.
29. - European Surveillance of Antibiotic Consumption (ESAC). http://www.esac.ua.ac.be/.
30. - European Surveillance System for Antimicrobial Resistance (EARSS). http://www.rivm.nl/earss/.
31. - World Health Organization (WHO). http://www.who.int/drugresistance/.